에 대한 최신 뉴스 Becton Dickinson (NYSE:BDX) 주식

Becton Dickinson

Becton, Dickinson

Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.

Kazan,,Russia,-,Dec,02,,2021:,Square,,Inc.,Changes,Name

Equities

Large Cap

News

Movers

Trading Ideas

COKE

FSLR

LINE

TRGP

지난주 가장 저조한 실적을 기록한 대형주는 다음과 같다. 블록, 코카콜라, 리니지, 벡톤 디킨슨, 웨스트레이크, 필그림스, 에코페트롤, 알라모스, YPF, 타르가

블록·코카콜라 등 지난주 급락한 대형주 10종목 (4월 28일~5월 2일)

S&P 500 Earnings Growth

AMZN

HOLX

ORCL

투자자들이 경제 낙관론, 기업 실적 호조, 트럼프 행정부의 주요 정책 변화 등을 소화하면서 S&amp;P 500 지수는 1월 마지막 주에 6,100포인트를 돌파하며 사상 최고치를 경신하고 있다.

1월 마지막 주에 상승할 수 있는 S&amp;P 500 주식 5종목은?

police-5226674_1280

Legal

EXPRQ

벡톤 디킨슨 1억 7천 5백만 달러의 민사 제재금 지급에 합의 증권거래위원회(SEC)는 월요일에 벡톤 디킨슨 앤 컴퍼니(NYSE:BDX), 즉 BD가 알라리스(Alaris) 주입 펌프의 지속적인 판매와 관련된 위험에 대해 투자자들을 반복적으로 오도하고, 펌프의 여러 소프트웨어 결함 수리 비용을 기록하지 않아 수입을 과대계상한 혐의로 제재를 해결했다고 발표했다. BD는 1억 7천 5백만 달러의 민사 제재금을 지급하기로 합의했다.

주간 금융 범죄: 벡톤 디킨슨에 $1억 7,500만 벌금, 익스프레스는 CEO 전액 보상 미공개

Becton, Dickinson and Company Common Stock

Becton Dickinson & Co

Shares of Becton Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027. Here's a breakdown of why the stock's structure looks weak under the lens of the Adhishthana Principles, our proprietary cyclical framework combining behavioral archetypes, timing structures, and quantitative signals.
<h3 class="wp-block-heading">BDX's Alignment So Far &amp; The 1400 Days of Consolidation</h3>
BDX began its Adhishthana Cycle on a strong note, showing consistent alignment with the framework during the early phases. However, a critical shift occurred as the stock entered Phase 8.
According to the Adhishthana Principles, a stock begins forming its Cakra from Phase 4, with the formation typically concluding by Phase 8. The Cakra, often a bullish arc-like structure, represents the preparation for a potential breakout in Phase 9.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="607" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana.png" alt="Fig.1 BDX Cakra Breakdown (Source: Adhishthana.com)" class="wp-image-14855" style="width:686px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana-300x152.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana-1024x518.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana-768x388.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 BDX Cakra Breakdown (Source: Adhishthana.com)</figcaption></figure>
In BDX's case, the Cakra formation broke down in Phase 8, a major deviation from the ideal path. Rather than respecting the lower arc of the Cakra and preparing for a breakout, BDX broke beneath it, signaling a shift into prolonged weakness and stalling bullish momentum.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"When the underlying breaks the Cākra on the flip side, it typically draws consolidation up to the Guna triads." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="371" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana.png" alt="Fig.2 BDX's Consolidation (Source: Adhishthana.com)" class="wp-image-14861" style="width:760px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana-300x93.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana-1024x317.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana-768x237.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 BDX&#8217;s Consolidation (Source: Adhishthana.com)</figcaption></figure>
True to this principle, BDX remained in a sideways consolidation for over 1,400 days, validating this structural breakdown.
<h3 class="wp-block-heading">The Guna Triads: A Major Red Flag</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="874" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana.png" alt="Fig.3 BDX's Guna Triads (Source: Adhishthana.com)" class="wp-image-14856" style="width:575px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana-300x219.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana-1024x746.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana-768x559.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.3 BDX&#8217;s Guna Triads (Source: Adhishthana.com)</figcaption></figure>
Phases 14, 15, and 16 in the Adhishthana framework are known as the Guna Triads. The triads determine whether a stock is capable of attaining Nirvana in Phase 18, which is the highest price point in its cycle.
BDX's triads were one of the weakest among peer stocks. They showed no signs of Satoguna, the essence of a clean and decisive bullish move. Instead, the structure appeared disjointed, with low momentum and unclear direction. This lack of energy suggests that Phase 18 will not result in a new high, and the stock is likely to remain in a corrective or consolidative mode until the cycle ends on 6 June 2027.&nbsp;
<h3 class="wp-block-heading">Monthly Chart Outlook: More Consolidation Ahead</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="587" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart-.png" alt="Fig.4 BDX's Monthly Chart (Source: Adhishthana.com)" class="wp-image-14859" style="width:633px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart--300x147.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart--1024x501.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart--768x376.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.4 BDX&#8217;s Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
On the monthly timeframe, BDX is currently in the Sankhya Period of Phase 2, typically characterized by bearish pressure and range-bound behavior. This phase extends until 2 August 2027, reinforcing the view that the stock is unlikely to gain significant bullish momentum in the near term.
<h3 class="wp-block-heading">Investor Takeaway: Avoid the Trap</h3>
The structural breakdown of the Cakra in Phase 8, coupled with weak Guna Triads and a bearish Sankhya move on the monthly charts, all point to one thing: BDX is not yet ready for a recovery yet. The stock's internal structure reflects deeper issues, possibly ethical or fundamental, and any rallies are likely to be short-lived traps.
Until the Adhishthana cycle realigns and shows strength in the later phases, investors are better off staying away from BDX. Long-term recovery isn't on the cards until after mid-2027 and that too only if stronger signs appear in the next cycle.

Technicals

Opinion

Signals

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

An official report on June 17, 2025 reveals Representative Thomas Kean's recent purchase of Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock, valued between $4,004 and $60,000. The transaction took place on May 8, 2025, as per the June filing.
At this time, Amazon.com shares are trading up 1.37% at $217.76.
<h3>Representative's Recent Trading Activity</h3>
In the last three years, Thomas Kean completed 95 stock transactions totaling more than $361 thousand. Aon and Johnson &amp; Johnson stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>): $1,001 - $15,000 Purchase</li>
<li>Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>): $1,001 - $15,000 Purchase</li>
<li>Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Thomas Kean's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aon</td>
<td>AON</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-27</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>BDX</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-13</td>
</tr>
<tr>
<td>Amazon.com</td>
<td>AMZN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-08</td>
</tr>
<tr>
<td>Crown Holdings</td>
<td>CCK</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-05-08</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>TMO</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-05</td>
</tr>
</tbody>
</table>
To keep an eye on Thomas Kean's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/thomas-kean">real-time tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

General

New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Know

Becton Dickinson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 3.26 million shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Becton Dickinson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749049256_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Becton Dickinson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Becton Dickinson's peer group average for short interest as a percentage of float is 5.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Becton Dickinson?

Barclays analyst Matt Miksic maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Overweight and lowers the price target from $261 to $241.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Becton Dickinson, Lowers Price Target to $241

BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex&#x2122; Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).
&nbsp;
Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex&#x2122; Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes.
"This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD," said Dr. Krishnan. "The Rotarex&#x2122; System has been extensively studied internationally, and we are excited to further evaluate its adaptability in treating a wide range of PAD lesions within the U.S. patient population."
The Rotarex&#x2122; Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries. Offering dual indications as both an atherectomy and thrombectomy device, the&nbsp;Rotarex&#x2122; Atherectomy System is a proven tool for treating PAD.

BD Launches US Patient Study to Track Real-World Results of Its PAD Treatment Device

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $215 to $230. Needham analyst Mike Cikos maintained a Buy rating. Snowflake shares closed at $179.12 on Wednesday. S<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) from $25 to $31. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. MediWound shares closed at $19.89 on Wednesday. <a href="https://www.benzinga.com/quote/MDWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) price target from $63 to $78. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Urban Outfitters shares closed at $59.60 on Wednesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased the price target for nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from $28 to $33. Needham analyst Mayank Tandon maintained a Buy rating. nCino shares closed at $25.48 on Wednesday. <a href="https://www.benzinga.com/quote/NCNO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup aslashed the price target for Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from $217 to $185. Citigroup analyst Joanna Wiensch downgraded the stock from Buy to Neutral. Becton, Dickinson shares closed at $173.14 on Wednesday. <a href="https://www.benzinga.com/quote/BDX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) price target from $13 to $8. Wedbush analyst Laura Chico downgraded the stock from Outperform to Neutral. Vigil Neuroscience shares settled at $2.31 on Wednesday. <a href="https://www.benzinga.com/quote/VIGL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised Integer Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) price target from $133 to $140. Citigroup analyst Joanne Wuensch upgraded the stock from Neutral to Buy. Integer Holdings shares closed at $118.88 on Wednesday. <a href="https://www.benzinga.com/quote/ITGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) price target from $90 to $100. Rosenblatt analyst Catharine Trebnick maintained a Buy rating. Zoom shares closed at $82.27 on Wednesday.  <a href="https://www.benzinga.com/quote/CM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased the price target for Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) from $4 to $6. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Navitas Semiconductor shares settled at $1.91 on Wednesday. <a href="https://www.benzinga.com/quote/NVTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) price target from $390 to $395. UBS analyst Kevin Mcveigh maintained a Buy rating. Accenture shares closed at $317.72 on Wednesday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ACN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-1024x586.png" alt="" class="wp-image-924453" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Markets

ITGR

MDWD

NCNO

NVTS

SNOW

URBN

VIGL

Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday

6 analysts have shared their evaluations of Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $218.5, along with a high estimate of $261.00 and a low estimate of $185.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.86%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747915222_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Becton Dickinson's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$196.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$224.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$261.00</td>
<td>$279.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Becton Dickinson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Becton Dickinson's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Becton Dickinson's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>Get to Know Becton Dickinson Better</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Financial Milestones: Becton Dickinson's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Becton Dickinson displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.5%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.84%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.56%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Have This To Say About Becton Dickinson

Citigroup analyst Joanna Wiensch downgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Buy to Neutral and lowers the price target from $217 to $185.

Downgrades

Citigroup Downgrades Becton Dickinson to Neutral, Lowers Price Target to $185

Hedge Funds

13F Shows Starboard Value Added 1.749M Stake In Becton, Dickinson and Company

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced on Wednesday that it will invest at least $20 billion in the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">U.S. through 2030</a>.
Research and development, plus U.S. manufacturing, will receive the bulk of the spending.
The company also expects higher job creation within the communities where Sanofi and its partners are located, which will help <a href="https://www.benzinga.com/pressreleases/25/05/n45414947/sanofi-to-invest-at-least-20-billion-in-the-us-through-2030-growing-investments-in-science-and-exp" target="_blank" rel="noreferrer noopener">enhance the U.S. supply chain</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a>
Sanofi has 13,000 US-based employees, according to CEO Paul Hudson.
&#8220;Our expected investments in the US will be substantial and will help ensure the production of key medicines in the U.S.,&#8221; he added.
Sanofi also expects to partner with other domestic manufacturers to help ensure the production of medicines in the U.S.  
Earlier in May, U.S. President&nbsp;Donald Trump's&nbsp;signed an executive order to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The White House wants facilities to come on board at a faster rate. It <a href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">estimates</a> that it can currently take five to 10 years to build new pharmaceutical manufacturing capacity, which it calls "unacceptable from a national-security standpoint.&#8221;
It&#8217;s not just Sanofi. <a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S.:
<ul class="wp-block-list">
<li>Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm&nbsp;Becton, Dickinson, and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)  seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;announced that it will invest $50 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Bristol-Myers Squibb &amp; Co.'s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Christopher Boerner, chair and chief executive officer,&nbsp;<a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">shared</a>&nbsp;plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Statnews.</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is one pharma company that did not highlight investments in new manufacturing plants. The company noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">products in the U.S</a>.
Price Action: Sanofi stock is down 1.53% at $49.20 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45407486/novo-nordisk-inks-22-billion-deal-with-septerna-to-develop-oral-weight-loss-and-diabetes-drugs" target="_blank" rel="noreferrer noopener">Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

REGN

RHHBY

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Despite a powerful 22% surge in the S&amp;P 500 since the April lows—driven by easing U.S.-China trade tensions and a 90-day pause on new tariffs—only half of the index&#8217;s stocks have managed to rise above their 200-day moving average, indicating a market rally <a href="https://www.benzinga.com/movers">that remains potentially incomplete.</a>
This technical indicator, often used to gauge long-term trends and market breadth, currently shows that just 49.9% of S&amp;P 500 components are in what traders would consider a bullish trend. 
That figure remains below both the five- and 10-year averages of 60%, suggesting a wide swath of the market has yet to participate in the rebound.
<h3 class="wp-block-heading">Breadth Gauge Shows Room To Run</h3>
Over the past four years, the percentage of stocks above their 200-day moving average has moved within a wide 10% to 92% range. The extreme lows—seen in June and September 2022 at just 10%—came during periods of heightened recession fears and monetary tightening. 
The recent cycle bottom occurred just last month, when the figure dipped to 15% following April's sharp, tariff-driven selloff.
The highest reading in the last four years came in May 2021, at 92%, during a time of peak post-pandemic optimism. More recently, a high of 82% was recorded in September 2024, following the start of Federal Reserve policy easing. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1024x529.png" alt="" class="wp-image-914932" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14083211/image-161-2048x1058.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What Analysts Say About The Tariff Pause and Market Reaction</h3>
Analysts say that the 90-day tariff truce announced in April and this week&#8217;s truce between the U.S. and China helped revive risk appetite, but they remain cautious about its long-term effects.
In a note on Wednesday, Peter Oppenheimer, strategist at Goldman Sachs, said the outcome was "much better than we had expected," noting that the tariff levies of 30 percentage points by the U.S. and +5 points by China were significantly lower than prior worst-case estimates.
Oppenheimer also highlighted that the new U.S.-UK trade agreement contributes to a more constructive global growth outlook and has mitigated fears of long-term economic damage from the April drawdown.
He added that the market has begun to price out recession risks. 
"Certainly, recent news has been supportive for risk in three respects: it has shown the U.S. Administration to be pragmatic and keen to de-escalate&#8230; it suggests a lower likely outcome for the average effective tariff rate&#8230; and it has led to a number of growth upgrades," he said.
Rick Gardner, chief investment officer at RGA Investments, said markets are already "pricing in an environment where the U.S. and China are able to trade with each other," even if some economic weakness persists.
"Even if we see a continued economic slowdown, the stock market may have already priced that in during the April selloff," Gardner said.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 20 Laggards – Price vs. 200-Day Moving Average</h3>
More than 20 S&amp;P 500 stocks are still trading over 20% below their 200-day moving averages, highlighting substantial technical room for recovery among the index's biggest underperformers during the tariff-relief rally. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>% Below 200-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.20%</td>
</tr>
<tr>
<td>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>-41.52%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-30.14%</td>
</tr>
<tr>
<td>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>)</td>
<td>-29.88%</td>
</tr>
<tr>
<td>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</td>
<td>-28.40%</td>
</tr>
<tr>
<td>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-27.11%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>)</td>
<td>-26.14%</td>
</tr>
<tr>
<td>Bio-Techne Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)</td>
<td>-24.95%</td>
</tr>
<tr>
<td>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)</td>
<td>-24.89%</td>
</tr>
<tr>
<td>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>-24.88%</td>
</tr>
<tr>
<td>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)</td>
<td>-24.48%</td>
</tr>
<tr>
<td>Teradyne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)</td>
<td>-24.35%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</td>
<td>-24.06%</td>
</tr>
<tr>
<td>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>-23.67%</td>
</tr>
<tr>
<td>Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-23.18%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>-23.06%</td>
</tr>
<tr>
<td>Becton, Dickinson and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>-22.80%</td>
</tr>
<tr>
<td>Halliburton Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>)</td>
<td>-22.30%</td>
</tr>
<tr>
<td>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>)</td>
<td>-21.76%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of May 13, 2025</figcaption></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market">SMCI Stock In &#8216;Sweet Spot,&#8217; Says Raymond James — Sets $41 Price Target As AI Revenue Hits 70%</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Economics

BIIB

ENPH

TECH

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?

New BD FACSDiscover&#x2122; A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.

BD Launches FACSDiscover A8 Cell Analyzer, Featuring Spectral And Real-Time Cell Imaging Technologies For Scientists In Academia And Biopharma

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Regulations

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

Morgan Stanley analyst Patrick Wood maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Overweight and lowers the price target from $280 to $196.

Morgan Stanley Maintains Overweight on Becton Dickinson, Lowers Price Target to $196

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) shares tumbled 19.90% after the company reported <a href="https://www.benzinga.com//node/45152696" target="_blank" rel="noreferrer noopener">worse-than-expected financial results</a>. Analysts slashed <a href="https://www.benzinga.com/quote/xyz/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) shares fell 18.93% after reporting worse-than-expected <a href="https://www.benzinga.com//node/45093641" target="_blank" rel="noreferrer noopener">first-quarter sales results</a>. Some analysts lowered the <a href="https://www.benzinga.com/quote/line/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) stock dipped 17.70%  after the company cut FY25 EPS guidance despite a hike in sales outlook. The company also missed <a href="https://www.benzinga.com//node/45140102" target="_blank" rel="noreferrer noopener">second-quarter revenue estimates</a>. Analysts cut <a href="https://www.benzinga.com/quote/bdx/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Coca-Cola (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) shares decreased 16.36%  after the company reported a year-over-year decrease in <a href="https://www.benzinga.com//node/45116927" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) stock fell 14.50% after the company reported worse-than-expected <a href="https://www.benzinga.com//node/45161312" target="_blank" rel="noreferrer noopener">first-quarter sales results</a>.</li>
<li>Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) stock dived 13.84% after the company reported worse-than-expected <a href="https://www.benzinga.com//node/45118399" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Ecopetrol S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) shares declined 12.27% probably amid a drop in oil and natural gas prices following a decline in U.S. first-quarter GDP, which could weigh on demand outlook.</li>
<li>Alamos Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) shares were down 11.59% after the company reported <a href="https://www.benzinga.com//node/45119634" target="_blank" rel="noreferrer noopener">first-quarter results below estimates</a>. The stock may also be down amid a drop in gold spot price.</li>
<li>YPF Sociedad Anonima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) stock fell 9.09%.</li>
<li>Targa Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) stock dived 8.87% after the company reported <a href="https://www.benzinga.com//node/45128247" target="_blank" rel="noreferrer noopener">earnings for the first quarter</a>.</li>
</ol>
Photo via Shutterstock

Block, Becton Dickinson And Pilgrim's Pride Are Among Top 10 Large-Cap Losers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

Becton Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) lowered its fiscal year 2025 guidance and provided an <a href="https://www.benzinga.com/pressreleases/25/05/n45128945/bd-reports-second-quarter-fiscal-2025-financial-results" target="_blank" rel="noreferrer noopener">estimated tariff impact </a>on Thursday.
The medical device company reported adjusted earnings per share of $3.35, up from $3.17 a year ago. It beat the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of $3.28</a>.
The company reported first-quarter 2025 sales of $5.27 billion, up 4.5% year-over-year, missing the consensus of $5.35 billion.
Becton Dickinson expects fiscal 2025 revenues of $21.8 billion and $21.9 billion. Its previously issued guidance of $21.7 billion to $21.9 billion reflects updated organic revenue growth guidance of 3.0% to 3.5% and an improvement in the <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">estimated impact of foreign currency</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
Goldman Sachs on Friday downgraded Becton Dickinson from Buy to Neutral, revising its <a target="_blank" href="https://www.benzinga.com/quote/BDX/analyst-ratings" rel="noreferrer noopener">price target from $256 to $192</a>.
Analyst David Roman says BDX stock has fallen 25% since being added to the Buy list on May 30, 2024, compared to the S&amp;P500&#8217;s 6% and their large-cap MedTech coverage of 5%.
&#8220;We think the underperformance reflects downward revisions in organic growth estimates despite ongoing strong P&amp;L results. Specifically, the forward outlook for organic revenue growth has shifted from ~5-6% two years ago to ~3-4%. This level of organic growth puts BD at the low-end of MedTech,&#8221; Roman added.
Goldman Sachs says because Becton Dickinson has a large share of its market, its growth is closely tied to how fast the overall market is growing. As the market has slowed, so have Becton Dickinson&#8217;s growth targets.
Some of these market challenges may ease over time. But Roman is less confident that Becton will return to steady mid-single-digit organic revenue growth by fiscal year 2026 — a key part of the investment case.
William Blair on Thursday downgraded Becton Dickinson to Market Perform following a disappointing fiscal second-quarter update.
&#8220;We have been wrong with our rating on this stock for several years, holding out hope that shares would see multiple expansion once the business found a new gear that resulted in more predictable revenue growth, margin expansion, and earnings growth,&#8221; analyst Andrew Brackmann writes.
William Blair writes that Becton, at its core, has the makeup to drive mid-single-digit revenue growth over an extended period.
However, that is not the case right now, making the near-term setup challenging— especially as the Bioscience and Diagnostics business is set to be separated but for which those businesses are seeing increased headwinds.
The analyst seeks greater confidence in a reacceleration in organic growth and looks to fiscal 2026 guidance and updates on the Bioscience and Diagnostics separation as key catalysts over the coming months.
Stifel maintains Becton Dickinson with a Buy, lowering the price target from $280 to $224.
Piper Sandler downgrades Becton Dickinson from Overweight to Neutral and lowers the price target from $260 to $185.
Price Action: BDX stock is down 1.36% at $167.24 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45171306/magna-shares-fall-as-profit-miss-overshadows-strong-sales-higher-outlook" target="_blank" rel="noreferrer noopener">Magna Shares Fall As Profit Miss Overshadows Strong Sales, Higher Outlook</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Wall Street extended its rally this week, fully erasing the losses suffered after the Trump administration's <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45172683/wall-street-eyes-9th-straight-day-of-gains-apple-falls-as-chinese-sales-disappoint-whats-driving-markets-friday">tariff announcement on April 2. </a>
Investor sentiment was buoyed by encouraging developments in trade negotiations and, most importantly, a stronger-than-expected start to earnings season.
Corporate America showed resilience in the face of trade headwinds. Mega-cap tech giants —including Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — all surpassed Wall Street estimates, with Microsoft logging its best weekly performance in years.
The S&amp;P 500 posted its second consecutive weekly gain, marking its longest winning streak since May 2024.
Top individual performers included Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) and Carrier Global Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>), both soaring roughly 20% for the week. On the downside, Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) tumbled 20%, making it the worst performer.
Michigan-based automaker General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) topped earnings forecasts yet withdrew guidance for the year amid "massive <a href="https://www.benzinga.com/news/earnings/25/05/45150325/gm-cut-its-2025-forecast-on-tariffs-but-core-business-holds-up-says-goldman-sachs">uncertainty&#8221; over tariffs.</a>
From a sector perspective, industrials and technology led the charge, while energy stocks lagged as crude oil prices slumped. Oil marked its second-worst week of the year, falling to $58 per barrel after Saudi Arabia signaled its readiness to cope with lower prices, stoking speculation that OPEC+ may boost output further in the coming months.
President Donald Trump's threat to impose secondary sanctions on nations buying Iranian oil failed to stabilize crude <a href="https://www.benzinga.com/government/regulations/25/05/45149446/oil-prices-soar-after-trump-threatens-sanctions-on-iranian-crude-buyers-is-china-on-top-of-the-list">prices, which continued to slide</a>.
Macroeconomic data painted a mixed picture. First-quarter gross domestic product shrank by 0.3%, missing forecasts of a 0.4% rise, largely due to a surge in imports.
Yet, inflation and employment data provided a more positive outlook. Nonfarm payrolls rose by 177,000 in April, beating the 130,000 consensus and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">underscoring labor market strength.</a>
Meanwhile, Personal <a href="https://www.benzinga.com/25/04/45102421/feds-key-inflation-gauge-cools-before-tariffs-hit-auto-outlays-spike-as-consumers-front-run-price-impacts">Consumption </a><a href="https://www.benzinga.com/25/04/45102421/feds-key-inflation-gauge-cools-before-tariffs-hit-auto-outlays-spike-as-consumers-front-run-price-impacts" target="_blank" rel="noopener">Expenditure inflation cooled</a>: annual price gains slowed from 2.7% in February to 2.3% in March. Core PCE, the Federal Reserve's preferred inflation gauge, eased to 2.6% year over year, aligning with expectations and down from 3%.
Looking ahead, markets will focus on the Federal Reserve's two-day policy meeting starting Tuesday. While no rate change is anticipated, Chair Jerome Powell's Wednesday press conference will be closely watched, especially after renewed calls from President Trump <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45166673/trump-pressures-fed-after-solid-jobs-cooling-inflation-lower-rates-now">to cut interest rates.</a>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45173740/5-great-income-buys-for-the-coming-downturn">5 Great Income Buys For The Coming Downturn</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Federal Reserve

Tech

ETFs

AAPL

ANET

CARR

MSFT

Wall Street Fully Recoups Tariff-Led Losses, Economy Contracts In First Quarter Yet April Payrolls Remain Strong: This Week In Markets

The U.S. stock market staged a stunning one-month rebound, fully erasing the losses triggered by Donald Trump&#8216;s <a href="https://www.benzinga.com/topic/donald-trump">April 2 tariff announcements.</a>
From its April low of 4,835 points, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—has surged 17.5%, logging nine consecutive sessions of gains through Friday, the longest winning streak since May 2024.
Still, the rally has been far from uniform across sectors.
The sectoral rebound since April has been powerful, but only a handful of sectors have managed to fully recover to or exceed their April 2 levels, before Trump&#8217;s tariff announcements triggered a broad selloff.
Technology led the charge, surging 25.9% since the April low and now stands 3.8% above its April 2 level, the strongest full recovery among all major sectors.
Industrials and Utilities also climbed 1.8% and 1% above their early-April levels, respectively.
Sectors like Consumer Discretionary , Communication Services, Financials, Consumer Staples, and Real Estate posted strong double-digit rebounds off April lows—ranging from 8.3% to 18.9%— finally reaching April 2 levels without breaching them.
On the other end of the spectrum, Energy remains 13.4% below its April 2 level, making it the worst laggard. Health Care is still down 4% from early April, even after recovering 7.2%. Materials also underperformed, ending the period 1.9% below its pre-tariff announcement level.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>%chg since April lows</th>
<th>May 2 vs. April 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>16.1%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>8.3%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>16.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>11.3%</td>
<td>-13.4%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>18.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>7.2%</td>
<td>-4%</td>
</tr>
<tr>
<td>Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>20.4%</td>
<td>up by 1.8%</td>
</tr>
<tr>
<td>Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>16.4%</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>17.2%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>25.9%</td>
<td>up by 3.8%</td>
</tr>
<tr>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>12.2%</td>
<td>up by 1%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top Performing S&amp;P 500 Stocks Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>Information Technology</td>
<td>41.22%</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>Communication Services</td>
<td>23.45</td>
</tr>
<tr>
<td>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)</td>
<td>Industrials</td>
<td>23.16</td>
</tr>
<tr>
<td>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</td>
<td>Industrials</td>
<td>20.78</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>Information Technology</td>
<td>18.92</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>Information Technology</td>
<td>18.87</td>
</tr>
<tr>
<td>ServiceNow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</td>
<td>Information Technology</td>
<td>18.80</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst Performer Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Information Technology</td>
<td>-26.66%</td>
</tr>
<tr>
<td>Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>Health Care</td>
<td>-25.89</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>Health Care</td>
<td>-23.76</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>Energy</td>
<td>-21.40</td>
</tr>
<tr>
<td>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>Financials</td>
<td>-20.95</td>
</tr>
<tr>
<td>Targa Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>)</td>
<td>Energy</td>
<td>-20.79</td>
</tr>
<tr>
<td>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>Health Care</td>
<td>-20.00</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45174409/nasdaq-100-leveraged-etf-tqqq-surges-55-as-tech-rally-jobs-data-boost-risk-appetite">Nasdaq-100 Leveraged ETF TQQQ Surges 5.5% As Tech Rally, Jobs Data Boost Risk Appetite</a></li>
</ul>
Photo: Shutterstock

AVGO

CRWD

NFLX

PLTR

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rosenblatt analyst Barton Crockett downgraded the rating for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Buy to Neutral and lowered the price target from $263 to $217. Apple shares closed at $213.32 on Thursday. <a href="https://www.benzinga.com/quote/aapl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Jeff Cantwell downgraded the rating for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Buy to Neutral. Block shares closed at $58.48 on Thursday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Maher Yaghi downgraded Thomson Reuters Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NASDAQ">TRI</a>) from Sector Outperform to Sector Perform and announced a price target of $188. Thomson Reuters shares closed at $185.74 on Thursday. <a href="https://www.benzinga.com/quote/TRI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Jason Bednar downgraded the rating for Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Overweight to Neutral and lowered the price target from $260 to $185. Becton Dickinson shares closed at $169.54 on Thursday. <a href="https://www.benzinga.com/quote/BDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Scott Devitt downgraded Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Outperform to Neutral and slashed the price target from $150 to $135. Airbnb shares closed at $124.01 on Thursday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-1024x586.png" alt="" class="wp-image-899761" style="width:507px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

ABNB

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

WIIM

Becton, Dickinson and Company shares are trading lower after Stifel maintained a Buy rating on the stock and lowered its price target from $280 to $224. Also, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $260 to $185.

Press Releases

BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support

BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair

Dividends

BD Board Declares Dividend

BD to Present at Bank of America Securities Health Care Conference

BD Reports Second Quarter Fiscal 2025 Financial Results

BD to Announce Financial Results for its Third Quarter of Fiscal 2025

BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies

Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

Abbott Laboratories

Baxter Intl

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Barclays

Citigroup

Morgan Stanley

Piper Sandler

Stifel

지난주 가장 저조한 실적을 기록한 대형주는 다음과 같다.
<ol>
<li>블록(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) 주가는 회사가 <a href="https://www.benzinga.com//node/45152696" target="_blank" rel="noreferrer noopener">예상보다 나쁜 재무 실적</a>을 발표한 이후 19.90% 급락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/xyz/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망</a>을 대폭 하향 조정했다.</li>
<li>리니지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) 주가는 예상보다 나쁜 <a href="https://www.benzinga.com//node/45093641" target="_blank" rel="noreferrer noopener">1분기 매출 실적</a>을 발표한 이후 18.93% 하락했다. 일부 애널리스트들은 <a href="https://www.benzinga.com/quote/line/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망</a>을 낮췄다.</li>
<li>벡톤 딕킨슨 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) 주가는 FY25 주당순이익(EPS) 가이던스를 하향 조정한 뒤 17.70% 하락했다. 회사는 매출 전망을 상향 조정했음에도 불구하고 <a href="https://www.benzinga.com//node/45140102" target="_blank" rel="noreferrer noopener">2분기 매출 예상치를 하회했다</a>. 애널리스트들은 <a href="https://www.benzinga.com/quote/bdx/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망</a>을 하향 조정했다.</li>
<li>코카콜라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) 주가는 전년 대비 감소한 <a href="https://www.benzinga.com//node/45116927" target="_blank" rel="noreferrer noopener">1분기 재무 실적</a>을 발표한 후 16.36% 하락했다.</li>
<li>웨스트레이크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) 주가는 예상보다 나쁜 <a href="https://www.benzinga.com//node/45161312" target="_blank" rel="noreferrer noopener">1분기 매출 실적</a>을 발표한 이후 14.50% 하락했다.</li>
<li>필그림스 프라이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) 주가는 예상보다 나쁜 <a href="https://www.benzinga.com//node/45118399" target="_blank" rel="noreferrer noopener">1분기 재무 실적</a>을 발표한 후 13.84% 급락했다.</li>
<li>에코페트롤(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) 주가는 미국의 1분기 GDP 감소에 따른 유가 및 천연가스 가격 하락으로 인해 12.27% 하락했다. 이는 수요 전망에 부정적인 영향을 미칠 수 있다.</li>
<li>알라모스 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) 주가는 예상치를 밑돈 <a href="https://www.benzinga.com//node/45119634" target="_blank" rel="noreferrer noopener">1분기 실적</a>을 발표한 후 11.59% 하락했다. 또한 금 현물 가격 하락으로 인해 주가가 하락할 수 있다.</li>
<li>YPF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) 주가는 9.09% 하락했다.</li>
<li>타르가 리소시스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) 주가는 <a href="https://www.benzinga.com//node/45128247" target="_blank" rel="noreferrer noopener">1분기 실적</a>을 발표한 후 8.87% 급락했다.</li>
</ol>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

투자자들이 경제 낙관론, 기업 실적 호조, 트럼프 행정부의 주요 <a href="https://www.benzinga.com/topic/donald-trump" target="_blank" rel="noopener">정책 변화</a> 등을 소화하면서 S&amp;P 500 지수는 1월 마지막 주에 6,100포인트를 돌파하며 사상 최고치를 경신하고 있다.
이러한 시장 상승세의 중심에는 도널드 트럼프가 있다. <a href="//www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now"" target="_blank" rel="noopener">새로 취임한</a> 제47대 미국 대통령은 <a href="//www.benzinga.com/government/regulations/25/01/43086509/trump-unleashes-executive-orders-on-border-security-oil-drilling-domestic-manufacturing-in-first-acts-as-president"" target="_blank" rel="noopener">무역, 이민, 석유</a>를 겨냥한 일련의 행정명령으로 첫 주를 시작했다. 일부 행정명령은 즉각적인 효과가 있는 것도 있고, 상징적인 것도 있으며, 일부는 법적 문제에 <a href="https://www.npr.org/2025/01/21/g-s1-44023/trump-birthright-citizenship-immigration-order-14th-amendment">직면해 있다.</a>
화요일에 트럼프는 5,000억 달러 규모의 프로젝트인 <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43135764/trumps-500-billion-stargate-ai-plan-puts-3-etfs-in-focus" target="_blank" rel="noopener">AI 스타게이트 계획을 공개</a>하기도 했다. 그리고 목요일, 트럼프는 다보스 <a href="https://www.youtube.com/watch?v=DKBWckduL2k" target="_blank" rel="noopener">화상 연설</a>을 통해 미국이 "인공지능과 암호화폐의 세계 수도"가 될 것이라고 선전했다.
한편, 조용한 흐름도 나타나고 있다. 1월 마지막 주는 역사적으로 주식에 긍정적인 시기였으며, 데이터에 따르면 몇몇 S&amp;P 500 종목이 큰 폭의 상승세를 보일 수 있다.
<h3>1월 마지막 주에 대한 낙관론 촉발</h3>
계절성이 항상 신뢰할 수 있는 시장 예측 변수는 아니지만, 패턴이 거의 한 세기 동안 지속될 때는 주의를 기울여야 한다. Seasonax의 데이터에 따르면 지난 97년 동안 1월은 평균 1.1%의 상승률로 60%의 시간 동안 플러스 영역에서 마감했다.
더욱 놀라운 점은 이러한 상승의 절반 이상이 월 마지막 주에 발생했다는 것다. 1928년 이후 S&amp;P 500 지수는 1월 마지막 주에 평균 0.6% 상승했으며, 61%의 기간 동안 상승 마감했다.
<h3>1월 말 상승 이력이 있는 주식 5종목</h3>
과거 패턴이 미래를 좌우하지는 않지만 종종 일치하는 경우가 있다. 20년간의 시장 데이터에 따르면 S&amp;P 500 주식 중 5개 종목이 1월 마지막 주에 꾸준히 초과수익을 기록했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>주식</th>
<th>평균 수익률 (1월 마지막 주)</th>
<th>상승 마감 (지난 20년)</th>
<th>최고 성과</th>
</tr>
</thead>
<tbody>
<tr>
<td>홀로직 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</td>
<td>4.08% (1월 23일 – 2월 2일)</td>
<td>20년 중 14년 상승</td>
<td>2005년 36.58%</td>
</tr>
<tr>
<td>아마존 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2.7% (1월 23일 – 1월 30일)</td>
<td>20년 중 16년 상승</td>
<td>2009년 16.2%</td>
</tr>
<tr>
<td>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>2.5% (1월 23일 – 2월 2일)</td>
<td>20년 중 14년 상승</td>
<td>2016년 21.04%</td>
</tr>
<tr>
<td>웰스파고 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>)</td>
<td>1.9% (1월 23일 – 1월 31일)</td>
<td>20년 중 13년 상승</td>
<td>2009년 21%</td>
</tr>
<tr>
<td>벡톤 디킨슨 앤 코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>1.56% (1월 23일 – 2월 2일)</td>
<td>20년 중 14년 상승</td>
<td>2005년 9.8%</td>
</tr>
</tbody>
</table>
</figure>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

1월 마지막 주에 상승할 수 있는 S&P 500 주식 5종목은?

벡톤 디킨슨 1억 7천 5백만 달러의 민사 제재금 지급에 합의
증권거래위원회(SEC)는 월요일에 벡톤 디킨슨 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), 즉 BD가 알라리스(Alaris) 주입 펌프의 지속적인 판매와 관련된 위험에 대해 투자자들을 반복적으로 오도하고, 펌프의 여러 소프트웨어 결함 수리 비용을 기록하지 않아 수입을 과대계상한 혐의로 <a href="https://www.sec.gov/newsroom/press-releases/2024-201">제재를 해결했다</a>고 발표했다. BD는 1억 7천 5백만 달러의 민사 제재금을 지급하기로 합의했다.
&#8220;BD는 투자자들에게 알라리스 주입 펌프에 대한 잘못된 그림을 반복적으로 제시하고, 2019년 말 FDA와의 문제로 기기가 문제가 발생했을 때 투자자들을 어둠 속에 가둬두는 방식으로 상황을 두 배로 악화시켰다&#8221;고 산제이 와드와(Sanjay Wadhwa) SEC 집행부 국장이 말했다.
&#8220;상장 회사들은 사업상의 중요한 위험을 정확하게 공개할 기본적인 의무가 있으며, 이 점에서 미비할 경우 책임을 져야 한다는 것을 기대해야 한다&#8221;고 와드와가 덧붙였다.
SEC의 명령은 BD가 연방 증권법의 사기 방지, 보고, 내부 회계 통제, 장부 및 기록, 공시 통제 조항을 위반했다고 밝혔다. BD는 이러한 조항에 대한 추가 위반을 중단하고, 공개 통제 및 절차에 관한 검토 및 권장 사항을 제공하기 위해 독립적인 규정 준수 컨설턴트를 고용하며, 1억 7천 5백만 달러의 민사 제재금에 동의했다. BD는 SEC의 조사 결과에 대해 인정하거나 부인하지 않았다.
익스프레스는 CEO의 전체 임원 보상을 공개하지 않음
SEC는 화요일에 패션 소매업체 익스프레스(OTC:<a class="ticker" href="https://www.benzinga.com/stock/EXPRQ#OTC">EXPRQ</a>)에 대해 현재 전 CEO에게 지급한 임원 보상을 공개하지 않은 혐의로 제재를 해결했다고 발표했다. 익스프레스는 SEC의 조사 결과를 인정하거나 부인하지 않고 중지 명령에 동의했다.
SEC의 명령에 따르면, 익스프레스는 2019, 2020 및 2021 회계연도 동안 CEO에게 제공된 979,269달러 상당의 특전 및 개인적 혜택을 공개하지 않았다. 결과적으로, 익스프레스는 CEO의 보상 중 &#8220;기타 보상&#8221; 부분을 3년 동안 평균 94% 과소계상했다. 회사는 올해 초 챕터 11 파산을 신청했다.
&#8220;상장 회사들은 임원 보상, 특전 및 개인적 혜택에 대한 공시 의무를 준수하여 투자자들이 정보에 입각한 투자 결정을 내릴 수 있도록 해야 한다&#8221;고 산제이 와드와 SEC 집행부 국장이 말했다.
&#8220;여기서 익스프레스는 의무를 다하지 못했지만, 위원회는 회사의 자진 보고, 조사에 대한 협력, 시정 노력 등을 고려하여 민사 제재금을 부과하지 않기로 결정했다&#8221;고 와드와가 덧붙였다.

다음 읽기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%B0%EC%A4%80%EC%9D%98-%EA%B8%88%EB%A6%AC%EC%9D%B8%ED%95%98%EC%99%80-2025%EB%85%84-%EC%A0%84%EB%A7%9D%EC%97%90-%EB%8C%80%ED%95%9C-%EC%A0%84%EB%AC%B8%EA%B0%80-%EC%9D%98%EA%B2%AC-%EC%98%AC/" target="_blank" rel="noopener">‘산타가 일찍 왔다&#8217; 그러나 연준은 ‘내년에는 석탄&#8217; : 전문가들이 금리 인하 및 2025년 전망에 대해 논의</a></li>
</ul>
이미지: Yildiray Yücel Kamanmaz from Pixabay
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식 시장은 목요일(7일) 연준이 예상대로 금리 인하를 결정하고, 제롬 파월 연준 의장이 <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res" target="_blank" rel="noopener"> 도널드 트럼프 당선</a> 이후 사임 또는 해임 가능성을 일축하며 시장을 안심시킨 기자회견 이후 사상 최고치로 마감했다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE" target="_blank" rel="noopener">SPY</a>)로 추적되는 S&amp;P 500 지수는 0.7% 상승한 5,973포인트로 마감했다.
기술주가 시장수익률을 초과 달성했으며, Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)로 추적되는 나스닥 100 지수는 1.5% 상승한 21,000포인트 사상 최고치를 기록했다.
특히, 마이크로소프트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE" target="_blank" rel="noopener">MSFT</a>), 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ" target="_blank" rel="noopener">AAPL</a>), 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ" target="_blank" rel="noopener">NVDA</a>), 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ" target="_blank" rel="noopener">GOOG</a>, <a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ" target="_blank" rel="noopener">GOOGL</a>), 아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ" target="_blank" rel="noopener">AMZN</a>), 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ" target="_blank" rel="noopener">META</a>), 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ" target="_blank" rel="noopener">TSLA</a>)로 구성된 &#8216;매그니피센트 세븐&#8217;의 총 시가총액이 17조 달러를 초과하여 새로운 정점을 기록했다.
다우존스 지수는 수요일에 3.6% 상승한 후 주춤했으며, 소형주 지수는 전날 5.8% 급등 후 0.4% 하락했다.
S&amp;P 500 지수에서 가장 성과가 좋았던 섹터는 기술 섹터로 1.8% 상승했으며, 통신서비스와 소비재 섹터가 각각 1.3% 상승했다. 수요일에 가장 많이 상승했던 금융주는 목요일에 1.5% 하락하면서 부진한 모습을 보였다.
<h3 class="wp-block-heading">연준, 금리인하 그리고 파월 거취 우려 일축</h3>
연방준비제도이사회는 예상대로 금리를 4.5%~4.75%로 0.25% 인하했는데, 이는 9월의 0.5% 대규모 인하 이후 완화 속도가 줄어든 것이다. 연준은 2분기 미국 국내총생산(GDP)이 2.8% 상승하고 소비자 신뢰가 회복되는 등 견고한 경제 모멘텀을 인정했다.
파월 의장은 10월 고용지표의 부진을 일축했으며, 일자리 성장 정체는 근본적인 경제 약세보다는 파업과 허리케인 같은 일시적인 요인에 기인한 것이라고 지적했다.
파월 의장은 이번 금리 인하를 통화 정책의 "추가 재조정(further recalibration)&#8221;의 일환으로 설명하며, 여전히 "제약적(restrictive)&#8221;이라고 했다. 그는 향후 추가 완화 가능성을 암시했지만 12월 회의에서 구체적인 금리 인하 시그널을 보내지 않고 데이터에 의존하는 접근 방식을 강조했다.
트럼프 대통령의 요청이 있으면 사임할 것이냐는 질문에 파월은 "아니오"라고 단호하게 답하며 대통령에게는 연준 의장을 해임할 법적 권한이 없다는 점도 거듭 강조했다.
파월 의장의 발언 이후 12월 금리 인하에 대한 시장 기대치는 75%까지 치솟으며 수요일 선거 이후 하락세를 회복했다. 국채수익률은 급격히 하락하여 10년물 수익률은 10bp 하락한 4.33%로 전날의 급등분을 거의 상쇄했다.
미국 달러는 0.7% 하락했으며, SPDR Gold Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE" target="_blank" rel="noopener">GLD</a>)로 추적되는 금 가격은 수요일 3% 하락한 후 목요일에는 1.8% 반등했다.
한편, 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)은 뉴욕시간 오후 4시 30분에 1% 상승 거래되었으며, 세션 중에 76,990달러로 사상 최고가를 기록했다.
<h3 class="wp-block-heading">목요일 S&amp;P 500 상위 5개 상승주</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>종가</td>
<td>변동 %</td>
</tr>
<tr>
<td>EPAM 시스템즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)</td>
<td>233.00</td>
<td>14.95%</td>
</tr>
<tr>
<td>비아트리스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</td>
<td>13.20</td>
<td>13.69%</td>
</tr>
<tr>
<td>슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>25.47</td>
<td>12.21%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>9.38</td>
<td>11.91%</td>
</tr>
<tr>
<td>맥케슨 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)</td>
<td>607.76</td>
<td>10.64%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">목요일 S&amp;P 500 상위 5개 하락주</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>이름</th>
<th>종가</th>
<th>변동 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>매치 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>)</td>
<td>31.11</td>
<td>-17.86%</td>
</tr>
<tr>
<td>APA 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.93</td>
<td>-11.34%</td>
</tr>
<tr>
<td>CVS 헬스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>57.09</td>
<td>-7.33%</td>
</tr>
<tr>
<td>로크웰 오토메이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>)</td>
<td>277.22</td>
<td>-5.71%</td>
</tr>
<tr>
<td>벡톤 디킨슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>227.16</td>
<td>-5.38%</td>
</tr>
</tbody>
</table>
</figure>
더 읽기: <a href="https://kr.benzinga.com/news/usa/economy/%EC%97%B0%EC%A4%80%EC%9D%98-%EA%B8%88%EB%A6%AC-%EC%9D%B8%ED%95%98-%EC%86%8D%EB%8F%84%EA%B0%80-%EB%91%94%ED%99%94%EB%90%A0-%EA%B2%83%EC%9C%BC%EB%A1%9C-%EC%98%88%EC%83%81-%EA%B2%BD%EC%A0%9C%ED%95%99/">연준의 금리 인하 속도가 둔화될 것으로 예상: 경제학자들, 트럼프의 백악관 복귀에 주목</a>
이미지: MidJourney 통해 인공지능으로 생성됨
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Bonds

Treasuries

Econ #s

$BTC

EPAM

GOOG

GOOGL

MTCH

NVDA

SMCI

TSLA

VTRS

파월 연설 후 미국 증시 사상 최고치, '매그니피센트 세븐' 총 시가총액 17조 달러 돌파

Comments

Becton Dickinson

뉴스

에 대한 최신 뉴스 Becton Dickinson (NYSE:BDX) 주식

일요일, 5월 04, 2025

금요일, 1월 24, 2025

일요일, 12월 22, 2024

목요일, 11월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌